ストックスクリーナーアプリを入手
0.905
0.11%
-0.001
アフターアワーズ：
.90
-0.005
-0.55%
前日終値:
$0.906
開ける：
$0.8891
24時間の取引高:
1.02M
Relative Volume:
0.28
時価総額：
$44.06M
収益：
-
当期純損益:
$-81.22M
株価収益率:
-0.3057
EPS:
-2.96
ネットキャッシュフロー:
$-74.41M
1週間 パフォーマンス:
-3.64%
1か月 パフォーマンス:
+30.78%
6か月 パフォーマンス:
+22.13%
1年 パフォーマンス:
+25.62%
1日の値動き範囲:
$0.81
$0.9799
1週間の範囲:
$0.81
$1.03
52週間の値動き範囲:
$0.58
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
XLO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.905 | 44.06M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-21 | 開始されました | Chardan Capital Markets | Buy |
| 2022-01-10 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-16 | 開始されました | Cowen | Outperform |
| 2021-11-16 | 開始されました | Guggenheim | Buy |
| 2021-11-16 | 開始されました | Morgan Stanley | Overweight |
| 2021-11-16 | 開始されました | Raymond James | Outperform |
すべてを表示
Xilio Therapeutics Inc (XLO) 最新ニュース
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest - Defense World
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times
Can Xilio's Novel Immunotherapy Platform Transform Cancer Treatment? CEO Reveals Latest Progress - StockTitan
Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 12.3% – Here’s What Happened - Defense World
Xilio (XLO) Stock Zooms 125% Higher On Cancer Fighting Deal with AbbVie - MSN
Xilio Therapeutics’ $2.1 Billion Collaboration With AbbVie - Global Legal Chronicle
Abbvie Inc. Reports 9.0 % Passive Stake In Xilio Therapeutics, Inc. As Of Feb 11SEC Filing - Marketscreener.com
Top Biotech Stocks To Keep An Eye OnFebruary 12th - MarketBeat
Stock summary: Xilio Therapeutics ended the week with a surge of 70.12% - Business Upturn
Latham Advises AbbVie on Collaboration and Option Agreement With Xilio Therapeutics and Related Equity Investment - Latham & Watkins LLP
Xilio shares soar on AbbVie collaboration deal - MSN
AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE
Top Biotech Stocks To Keep An Eye On – February 12th - Defense World
AbbVie Deal Unmasks Promise Of Xilio’s T-Cell Engagers - News & Insights
Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld Online
Xilio Therapeutics: Innovative TCE Platform and Strategic AbbVie Partnership Justify Buy Rating - TipRanks
AbbVie and Xilio Therapeutics announce collaboration and option agreement - MSN
We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - Simply Wall St
Petri Dish: a new AbbVie deal, layoffs, and CFO departures - The Business Journals
AbbVie partners with Xilio to develop tumour-activated immunotherapies - World Pharmaceutical Frontiers
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Yahoo Finance
Xilio Gains 125% on New Deal with AbbVie to Target Prostate and Other Cancers - PUNE.NEWS
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio - sharewise
AbbVie pens another T cell engager deal, this time with Xilio - Endpoints News
AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace
Xilio soars after tie-up with AbbVie to develop cancer treatments - TradingView
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Benzinga
Stock market today: Spire Global plunged by 48.97% while Xilio Therapeutics surged by 102.16% in early trading - Business Upturn
AbbVie inks another billion-dollar oncology deal - Crain's Chicago Business
AbbVie, Xilio Hook up - Baystreet.ca
AbbVie expands oncology R&D with Xilio deal - The Pharma Letter
Xilio Therapeutics, Intel, Lithia Motors - TradingView
Xilio Therapeutics Shares Surge Premarket on AbbVie Deal -February 12, 2025 at 08:42 am EST - Marketscreener.com
Abbvie and Xilio Therapeutics, Inc. Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Marketscreener.com
AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech
Xilio Therapeutics Partners with AbbVie for Immunotherapy Expansion - TipRanks
Xilio shares soar on AbbVie collaboration deal By Investing.com - Investing.com Nigeria
AbbVie and Xilio Therapeutics announce collaboration - TipRanks
Abbvie And Xilio Therapeutics Announce Collaboration -February 12, 2025 at 07:51 am EST - Marketscreener.com
AbbVie and Xilio partner for tumor-activated therapies - Investing.com
Xilio Therapeutics Announces Collaboration with AbbVie to Advance Novel Tumor-Activated Immunotherapies with $52 Million Upfront Payment - Nasdaq
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewswire
Major Biotech Partnership: Xilio Secures $52M AbbVie Deal with Massive $2.1B Milestone Potential - StockTitan
Major Cancer Breakthrough: AbbVie Invests $52M in Xilio's Revolutionary Tumor-Fighting Technology - StockTitan
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - PR Newswire
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034 - GlobeNewswire Inc.
Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Inc (XLO) 財務データ
収益
当期純利益
現金流量
EPS
Xilio Therapeutics Inc (XLO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
| GILEAD SCIENCES, INC. | 10% Owner |
Apr 02 '24 |
Buy |
0.76 |
485,250 |
368,790 |
7,345,473 |
6.45%
1.23%
大文字化:
|
ボリューム (24 時間):